Serum Institute's Adar Poonawalla Hails WHO's Approval Of Covovax Vaccine

The World Health Organization has listed Covovax as the ninth COVID-19 vaccine for emergency use with an aim to increase the access to vaccination in lower-income countries.

Serum Institute of India (SII) CEO Adar Poonawalla on Friday hailed WHO's approval for emergency use of Covovax vaccine for children "as yet another milestone" in the fight against COVID-19. This is yet another milestone in our fight against COVID-19, Covovax is now W.H.O. approved for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration, @Novavax@WHO@GaviSeth@Gavi@gatesfoundationhttps://t.co/7C8RVZa3Y4

The World Health Organization (WHO) on Friday listed the Covovax as the ninth COVID-19 vaccine for emergency use with an aim to increase the access to vaccination in lower-income countries.

It is produced by the Serum Institute of India under the licence from Novavax.

Reacting to the development, Mr Poonawalla tweeted, "This is yet another milestone in our fight against COVID-19, Covovax is now WHO approved for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration..." He tagged Novavax, WHO, Gavi, the Vaccine Alliance, its CEO Seth Berkley and the Gates Foundation.